The Cancer-killing“oncolytic” viruses, which was derived from herpes, made their way into oncology practices in 2015 with Amgen’s melanoma drug Imlygic being approved.
Biogen announced Tuesday that it has agreed to enter a $1.25-billion settlement and licensing agreement with Forward Pharma under which it will obtain an irrevocable license to all of the latter's intellectual property.